REGENXBIO Statistics
NASDAQ: RGNXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
7.56-0.035 (-0.46%)
Market open · Delayed 15 min · as of Oct 8, 9:58 AM ET
REGENXBIO by the numbers
REGENXBIO has a market capitalization of $499.1 million based on 66.01M shares outstanding. With trailing EPS of $-3.78, REGENXBIO is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 17.4% below its 50-day average and 22.8% below its 200-day average.
Average daily trading volume is 1.52M shares, or about $11.5 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
RGNX valuation vs. peer median
| Metric | RGNX | Peer median | Difference |
|---|---|---|---|
| Market cap | $499.06M | $451.63M | +11% |
| Avg. volume | 1.52M | 1.38M | +10% |
Peer median across 8 companies: ALLO, AUTL, VALN, AGMB, TECX, ENTX, ETRA, EDIT.
Valuation
- Market cap
- $499.06M
- EPS (TTM)
- $-3.78
- Shares outstanding
- 66.01M
Price and trading
- Previous close
- 7.60
- Open
- 7.50
- Day range
- 7.44 – 7.58
- 52-week range
- 5.46 – 16.19
- 52-week change
- -27.74%
- Beta
- —
- Volume
- 82.26K
- Average volume
- 1.52M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 5, 2026
Additional statistics
- Market Cap
- 499.06M
- Forward Pe
- -2.54
- Eps
- -3.78
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 16.19
- Week52 Low
- 5.46
- Avg Volume
- 1.52M
- Shares Outstanding
- 66.01M
- Ma50
- 9.15
- Ma200
- 9.79
- Earnings Date
- Nov 5, 2026
- Pct From52w High
- -53.30%
- Pct From52w Low
- 38.59%